Liver Disease
News
Novel HCV therapy leads to rapid response
Major finding: Among hepatitis C patients who received the protease inhibitor danoprevir in addition to a regimen of peginterferon alfa-2a/...
News
Management of patients with hepatobiliary disorders
News
Pentoxifylline/Prednisolone doesn’t improve survival in alcoholic hepatitis
Major Finding: In the intention-to-treat analysis, 6-month survival did not differ between the combination-therapy group (69.9%) and the single-...
News
Medicare considers coverage of hepatitis C screening
News
Sofosbuvir combo effective in unresponsive HCV
Major Finding: Sixty-eight percent of patients who took sofosbuvir plus weight-based doses of ribavirin and 48% of those who took sofosbuvir plus...
News
Interferon-free regimens effective for hepatitis C virus genotype 1
Major finding: The primary efficacy endpoint – a sustained virologic response (an undetectable plasma level of HCV RNA) 12 weeks after the...
From the AGA Journals
High discontinuation rate noted for direct-acting antiviral therapy
Major finding: By 24 weeks, 74% of hepatitis C patients taking boceprevir and 60% taking telaprevir had an early virologic response, but nearly...
From the AGA Journals
Triple therapy underutilized in HCV
Major finding: From a cohort of nearly 500 hepatitis C patients, 91 (18.7%) were started on triple therapy.Data source: A retrospective, 1-year,...
From the AGA Journals
New estimates show lack of progress in liver mortality
Major finding: An updated definition of liver-related mortality shows that death rates are unchanged over 30 years: 23.9 per 100,000 persons for...
News
‘HCC-4 risk score’ IDs hepatitis C patients likely to develop HCC
Major finding: The annual incidence of HCC was 0.06% in the group designated as low risk, 0.5% in the group designated as medium risk, and 2.6% in...